Ultragenyx and Kyowa Kirin announce publication of phase 2 study results
Ultragenyx and Kyowa Hakko Kirin announced that results of a pediatric Phase 2 clinical trial of Crysvita® (burosumab) for treatment of X-linked hypophosphatemia in children aged 5 to 12 years were published by the NEJM. Topline results from this study were previously announced in April 2017. May 23, 2018